US6362325B1
(en)
*
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
US20060002904A9
(en)
*
|
1988-11-07 |
2006-01-05 |
Kwon Byoung S |
Receptor and related products and methods
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US20060063923A1
(en)
*
|
1992-07-30 |
2006-03-23 |
Kwon Byoung S |
4-1BB peptides and methods for use
|
CA2429027C
(en)
*
|
1993-09-16 |
2011-04-05 |
Indiana University Foundation |
Antibodies against human receptor h4-1bb
|
CN1232402A
(zh)
*
|
1996-10-11 |
1999-10-20 |
布里斯托尔-迈尔斯斯奎布公司 |
免疫调节的方法和组合物
|
US6051228A
(en)
*
|
1998-02-19 |
2000-04-18 |
Bristol-Myers Squibb Co. |
Antibodies against human CD40
|
US20030096976A1
(en)
*
|
1998-11-17 |
2003-05-22 |
Hong Hyo Jeong |
Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
|
KR20000034847A
(ko)
*
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
US20040001863A1
(en)
*
|
1998-12-03 |
2004-01-01 |
Shau-Chi Chi |
Immortal cell line derived from grouper Epinephelus coioides and its applications therein
|
ES2629683T3
(es)
|
1999-11-30 |
2017-08-14 |
Mayo Foundation For Medical Education And Research |
B7-H1, una nueva molécula inmunorreguladora
|
BR0111158A
(pt)
|
2000-05-12 |
2004-04-06 |
Genzyme Corp |
Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
|
US7320789B2
(en)
*
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
ES2328025T3
(es)
|
2001-10-09 |
2009-11-06 |
Mayo Foundation For Medical Education And Research |
Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
|
EP1543034A4
(de)
*
|
2002-07-15 |
2006-11-08 |
Mayo Foundation |
Behandlung und prophylaxe mit 4-1bb-bindenden mitteln
|
PL375144A1
(en)
*
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
EP1388544A1
(de)
*
|
2002-07-31 |
2004-02-11 |
D. Collen Research Foundation vzw |
Anti-Idiotypische Antikörper gegen Factor VIII-Inhibitor und Verwendungen davon
|
EP1545578A4
(de)
*
|
2002-08-28 |
2010-07-07 |
Immunex Corp |
Zusammensetzungen und verfahren zur behandlung von herz-kreislauf-erkrankungen
|
EP1575672A2
(de)
*
|
2002-12-16 |
2005-09-21 |
Herbert Schwarz |
Verwendung von cd137-antagonisten zur behandlung von tumoren
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
US7674884B2
(en)
*
|
2003-12-10 |
2010-03-09 |
Novimmune S.A. |
Neutralizing antibodies and methods of use thereof
|
PT1810026T
(pt)
|
2004-10-06 |
2018-06-11 |
Mayo Found Medical Education & Res |
B7-h1 e pd-1 no tratamento do carcinona de células renais
|
US20080019905A9
(en)
*
|
2005-02-18 |
2008-01-24 |
Strome Scott E |
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
|
US20060182744A1
(en)
*
|
2005-02-15 |
2006-08-17 |
Strome Scott E |
Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
NZ568433A
(en)
*
|
2005-10-21 |
2012-07-27 |
Gtc Biotherapeutics Inc |
Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
US20110020325A1
(en)
*
|
2008-02-29 |
2011-01-27 |
Kwon Eugene D |
Methods for reducing granulomatous inflammation
|
WO2009134389A2
(en)
*
|
2008-05-01 |
2009-11-05 |
Gtc Biotherapeutics, Inc. |
An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
JP6018917B2
(ja)
*
|
2009-12-07 |
2016-11-02 |
デシミューン セラピューティクス,インコーポレイテッド |
抗炎症抗体およびその使用
|
WO2014165115A1
(en)
|
2013-03-12 |
2014-10-09 |
Decimmune Therapeutics, Inc. |
Humanized anti-n2 antibodies
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
WO2015069703A1
(en)
|
2013-11-06 |
2015-05-14 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
ES2783026T3
(es)
|
2014-02-04 |
2020-09-16 |
Pfizer |
Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
EP3171896A4
(de)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
|
AU2016291817A1
(en)
|
2015-07-16 |
2018-02-22 |
Biolinerx Ltd. |
Compositions and methods for treating cancer
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
WO2018098401A1
(en)
|
2016-11-23 |
2018-05-31 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
MA47236A
(fr)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des agonistes de la superfamille des récepteurs du facteur de nécrose tumorale (tnfrsf) et des combinaisons thérapeutiques de til et d'agonistes de tnfrsf
|
KR20190107097A
(ko)
|
2017-01-20 |
2019-09-18 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd137+ 세포의 고갈을 위한 조성물 및 방법
|
US11819517B2
(en)
|
2017-06-05 |
2023-11-21 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
WO2019036855A1
(en)
*
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
ANTI-CD137 MOLECULES AND THEIR USE
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
TWI701259B
(zh)
*
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
4﹘1bb抗體及其製備方法和應用
|
EP3710576A1
(de)
|
2017-11-17 |
2020-09-23 |
Iovance Biotherapeutics, Inc. |
Til-expansion von feinnadelaspiraten und kleinen biopsien
|
EP3713961A2
(de)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
CN117866899A
(zh)
|
2018-01-08 |
2024-04-12 |
艾欧凡斯生物治疗公司 |
产生富含肿瘤抗原特异性t细胞的til产品的方法
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
US20210363266A1
(en)
*
|
2018-01-22 |
2021-11-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
JP2021512962A
(ja)
|
2018-02-13 |
2021-05-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ
|
SG11202009170UA
(en)
|
2018-03-29 |
2020-10-29 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
US20210230287A1
(en)
*
|
2018-04-10 |
2021-07-29 |
Wuxi Biologics (Shanghai) Co., Ltd. |
A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
|
CA3098303A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
WO2019217753A1
(en)
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
KR20210064269A
(ko)
|
2018-09-20 |
2021-06-02 |
이오반스 바이오테라퓨틱스, 인크. |
동결보존된 종양 샘플로부터의 til의 확장
|
JOP20210094A1
(ar)
|
2018-11-05 |
2023-01-30 |
Iovance Biotherapeutics Inc |
عمليات لإنتاج الخلايا الليمفاوية للورم الارتشاحي واستخداماتها في العلاج المناعي
|
CN113272420A
(zh)
|
2018-11-05 |
2021-08-17 |
艾欧凡斯生物治疗公司 |
经改进的肿瘤反应性t细胞的选择
|
WO2020096927A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
WO2020131547A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
MX2021011608A
(es)
|
2019-03-29 |
2021-12-10 |
Myst Therapeutics Llc |
Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
WO2021020845A1
(en)
*
|
2019-07-26 |
2021-02-04 |
Abl Bio Inc. |
Anti-egfr/anti-4-1bb bispecific antibody and use thereof
|
EP4048295A1
(de)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Genbearbeitung von tumorinfiltrierenden lymphozyten und deren verwendungen in der immuntherapie
|
JP2023504042A
(ja)
|
2019-11-27 |
2023-02-01 |
ミスト セラピューティクス リミテッド ライアビリティ カンパニー |
調節物質を使用した腫瘍反応性t細胞組成物の生成方法
|
WO2021118990A1
(en)
|
2019-12-11 |
2021-06-17 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
BR112022016490A2
(pt)
|
2020-02-27 |
2022-10-11 |
Myst Therapeutics Llc |
Métodos para enriquecimento ex vivo e expansão de células t reativas tumorais e composições relacionadas das mesmas
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
JP2023524108A
(ja)
|
2020-05-04 |
2023-06-08 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
改良された腫瘍反応性t細胞の選択
|
JP2023523855A
(ja)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
|
JP2023533755A
(ja)
*
|
2020-07-09 |
2023-08-04 |
ランケナウ・インスティテュート・フォー・メディカル・リサーチ |
ヒトido-2に対する抗体を含む組成物
|
JP2023546359A
(ja)
|
2020-10-06 |
2023-11-02 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球療法によるnsclc患者の治療
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
AU2021401302A1
(en)
|
2020-12-17 |
2023-07-06 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
EP4262827A1
(de)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Behandlung von krebs mit tumorinfiltrierenden lymphozyten
|
EP4288140A1
(de)
|
2021-02-05 |
2023-12-13 |
Iovance Biotherapeutics, Inc. |
Adjuvante therapie für krebs
|
TW202300014A
(zh)
|
2021-03-05 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
腫瘤儲存及細胞培養組成物
|
KR20240037185A
(ko)
|
2021-04-19 |
2024-03-21 |
이오반스 바이오테라퓨틱스, 인크. |
키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|